



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/834,321
(use as many sheets as necessary)				Filing Date	April 13, 2001
Sheet	1	of	1	First Named Inventor	Jeffrey V. Ravetch
				Group Art Unit	1644
				Examiner Name	Michail A. Belyavskyi
				Attorney Docket Number	RFU0001-100 (RU-479)


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
MAB		CLYNES et al., "Inhibitory Fc Receptors Modulate In Vivo Cytotoxicity Against Tumor Targets," <i>Nature Medicine</i> , Vol. 6, No. 4, 2000, pp. 1078-8956.			
		D'AMBROSIO ET AL., "The SHP Phosphate 1-15 Becomes Associated With FcγRIIB1 And Is Tyrosine Phosphorylated During Negative Signaling," <i>Immunology Letters</i> , 1996, Vol. 54, No. 2-3, pp. 77-82.			
		LIU et al., "Protein Tyrosine Phosphorylation Triggered By Human FcγRIIa," <i>Biochemical And Biophysical Research Communications</i> , Vol. 201, No. 2, pp. 829-834.			
		MURAILLE et al., "The SH2 Domain Containing Inositol 5-Phosphatase SHIP2 Associates To The Immunoreceptor Tyrosine-Based Inhibition Motif Of FcγRIIB In B Cells Under Negative Signaling," <i>Immunology Letters</i> , 2000, Vol. 72, No. 1, pp. 7-15.			
MAB		European Search Report dated August 16, 2004 for European Search Report 01 82 6962.			

Examiner Signature		Date Considered	5/22/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2008. OMB 0651-0031
S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Subject to a collection of information under 5 U.S.C. § 552. Contains a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Substitute for form 1449B-PC~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

of 1

Attorney Docket Number

Complete if Known

09/834,321

April 13, 2001

Jenley V. Ravelch

104

Michael A. Belyavsky

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PWS		HOUGHTON AN and SCHEINBERG DA, "Monoclonal Antibody Therapies - a 'Constant' Threat to Cancer", NATURE MEDICINE, Vol. 6, No. 4, April 2000, pages 373-374	

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

¹Applicant's unique citation identification number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). - Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.